专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0174788A8 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE 审中-公开
标题翻译：用于抗生素使用的2-羟基 - 木质素衍生物
公开(公告)号：WO0174788A8
公开(公告)日：2001-12-20
申请号：PCT/EP0103594
申请日：2001-03-29
申请人： SMITHKLINE BEECHAM PLC , BROOKS GERALD , HUNT ERIC , HOWARD STEVEN
发明人： BROOKS GERALD , HUNT ERIC , HOWARD STEVEN
IPC分类号： C07D237/24 , A61K31/426 , A61K31/44 , A61K31/4409 , A61K31/495 , A61K31/4985 , A61K31/50 , A61K31/505 , A61K31/519 , A61P31/04 , C07D213/81 , C07D213/82 , C07D233/61 , C07D239/42 , C07D241/26 , C07D277/20 , C07D277/56 , C07D417/04 , C07D471/04 , C07D487/04 , A61K31/425
CPC分类号： C07D417/04 , C07D213/81 , C07D239/42 , C07D277/56 , C07D487/04
摘要： 2-(S)-hydroxymutilin carbamate derivatives of formula (I), in which R is a 5- or 6-membered optionally substituted heteroaryl group; and R is vinyl or ethyl, are useful in the treatment of bacterial infections.
摘要翻译：式（I）的2-（S） - 羟基木丁酯氨基甲酸酯衍生物，其中R 1为5-或6-元任意取代的杂芳基; 和R 2是乙烯基或乙基，可用于治疗细菌感染。

2. 发明申请

WO2006070195A8 PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES 审中-公开
标题翻译：调节CDK，GSK和AURORA KINASES活性的吡咯化合物
公开(公告)号：WO2006070195A8
公开(公告)日：2006-08-24
申请号：PCT/GB2005005097
申请日：2005-12-30
申请人： ASTEX THERAPEUTICS LTD , BERDINI VALERIO , CARR MARIA GRAZIA , GILL ADRIAN LIAM , HOWARD STEVEN , NAVARRO EVA FIGUEROA , TREWARTHA GARY , REES DAVID CHARLES , VINKOVIC MLADEN , WYATT PAUL GRAHAM
发明人： BERDINI VALERIO , CARR MARIA GRAZIA , GILL ADRIAN LIAM , HOWARD STEVEN , NAVARRO EVA FIGUEROA , TREWARTHA GARY , REES DAVID CHARLES , VINKOVIC MLADEN , WYATT PAUL GRAHAM
IPC分类号： C07D403/04 , A61K31/4184 , A61P35/00 , C07D407/14 , C07D513/04
CPC分类号： C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/14 , C07D487/04 , C07D513/04
摘要： The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.
摘要翻译：本发明提供式（I）化合物或其盐，溶剂化物，互变异构体或N-氧化物，其中M选自D1和D2组：R'，E，A和X如上所定义在权利要求中。还提供了含有化合物的药物组合物，制备该化合物的方法以及该化合物在预防或治疗由CDK激酶，GSK-3激酶或极光激酶介导的疾病状态中的用途。

3. 发明申请

WO2010042879A3 EXPANDABLE SLIDE AND LOCK STENT 审中-公开
标题翻译：可扩展的滑盖和锁杆
公开(公告)号：WO2010042879A3
公开(公告)日：2010-06-10
申请号：PCT/US2009060256
申请日：2009-10-09
申请人： REVA MEDICAL INC , SCHMID ERIC , MORRIS ANDREW , WEIER KEITH , BONSIGNORE CRAIG , ESSER KEITH , HOWARD STEVEN , DIPARI JOE
发明人： SCHMID ERIC , MORRIS ANDREW , WEIER KEITH , BONSIGNORE CRAIG , ESSER KEITH , HOWARD STEVEN , DIPARI JOE
IPC分类号： A61F2/92
CPC分类号： A61F2/93 , A61F2/92 , A61F2220/0016 , A61F2230/0091 , B33Y80/00
摘要： An expandable slide and lock stent is provided that comprises a plurality of radial elements interconnected to form a tubular member. Each radial element can comprise a helical backbone and at least one elongate member extending from the helical backbone in a circumferential direction. Each backbone can have at least one slot that can be configured to receive an elongate member of an adjacent radial element.
摘要翻译：提供了一种可扩展的滑动和锁定支架，其包括互连以形成管状构件的多个径向元件。每个径向元件可以包括螺旋骨架和至少一个在圆周方向上从螺旋骨架延伸的细长构件。每个骨架可以具有至少一个狭槽，其可被构造成接收相邻径向元件的细长构件。

4. 发明申请

WO2008007123A3 PHARMACEUTICAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：WO2008007123A3
公开(公告)日：2008-02-28
申请号：PCT/GB2007002655
申请日：2007-07-13
申请人： ASTEX THERAPEUTICS LTD , NOVARTIS AG , CONGREVE MILES STUART , GILL ADRIAN LIAM , HOWARD STEVEN , MORTENSON PAUL NEIL , BESONG GILBERT EBAI
发明人： CONGREVE MILES STUART , GILL ADRIAN LIAM , HOWARD STEVEN , MORTENSON PAUL NEIL , BESONG GILBERT EBAI
IPC分类号： C07D401/12 , A61K31/4155 , A61P25/28 , A61P31/10 , A61P31/12 , A61P35/00 , A61P37/00 , C07D401/14 , C07D417/12 , C07D497/04
CPC分类号： C07D417/12 , C07D401/12 , C07D401/14 , C07D513/04
摘要： The invention provides a cyclin dependent kinase (e.g. cdk-4 kinase) inhibitor of the formula (I) or a salt, tautomer, solvate or N-oxide thereof; wherein R 1 is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group containing 0-2 heteroatoms selected from O, N and S wherein the optional substituents are selected from halogen, C 1-4 alkyl, C 1-4 alkoxy, C 3-4 cycloalkyl and cyano, and wherein the C 1-4 alkyl and C 1-4 alkoxy groups are each optionally further substituted by C 1-2 alkoxy or one or more halogen atoms; and E is a group E1, E2, E3 or E4: formulae E1, E2, E3, E4 wherein n, q, A5 B, T, U, V, W, Z, R 2 , R 5 , R 6 and R 7 are as defined in the claims.
摘要翻译：本发明提供式（I）的细胞周期蛋白依赖性激酶（例如cdk-4激酶）抑制剂或其盐，互变异构体，溶剂化物或N-氧化物; 其中R 1是任选取代的含有0-2个选自O，N和S的杂原子的单环或双环芳基或杂芳基，其中任选的取代基选自卤素，C 1-4烷基，烷基，C 1-4烷氧基，C 3-4环烷基和氰基，并且其中C 1-4烷基和C 1-4烷基 1-4烷氧基各自任选进一步被C 1-2烷氧基或一个或多个卤素原子取代; 和E是基团E1，E2，E3或E4：式E1，E2，E3，E4其中n，q，A5 B，T，U，V，W，Z，R 2，R R5，R6和R7如权利要求中所定义。

5. 发明申请

WO2010124032A3 TRANSVERSE CONNECTORS 审中-公开
标题翻译：横向连接器
公开(公告)号：WO2010124032A3
公开(公告)日：2011-04-21
申请号：PCT/US2010031958
申请日：2010-04-21
申请人： SPINAL ELEMENTS INC , BLAIN JASON , MARTIN GREG , HOWARD STEVEN
发明人： BLAIN JASON , MARTIN GREG , HOWARD STEVEN
IPC分类号： A61B17/70 , A61B17/84 , A61B17/86
CPC分类号： A61B17/7052
摘要： Devices and methods are disclosed for treating the vertebral column. One embodiment provides a transverse connector for vertebral fixation systems comprising a first connector body comprising a first engaging member for engaging a first elongate member and a first locking member, a second connector body comprising a second engaging member for engaging a second elongate member, and a transverse rod coupled to the first connector body and the second connector body, thereby forming an articulation between a first end of the transverse rod and the first connector body, wherein the first locking member is configured to secure both the articulation and the first elongate member to the first connector body.
摘要翻译：公开了用于治疗脊柱的装置和方法。一个实施例提供了一种用于脊椎固定系统的横向连接器，包括第一连接器本体，第一连接器本体包括用于接合第一细长构件和第一锁定构件的第一接合构件，第二连接器主体，包括用于接合第二细长构件的第二接合构件，横向杆联接到第一连接器主体和第二连接器主体，由此在横向杆的第一端和第一连接器主体之间形成铰接，其中第一锁定构件构造成将铰接和第一细长构件固定到第一个连接器体。

6. 发明申请

WO2006136829A3 PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS 审中-公开
标题翻译：吡唑衍生物及其作为PKA和PKB调节剂的用途
公开(公告)号：WO2006136829A3
公开(公告)日：2007-02-15
申请号：PCT/GB2006002286
申请日：2006-06-21
申请人： ASTEX THERAPEUTICS LTD , CANCER RES INST ROYAL , ASTRAZENECA AB , CANCER RESEARCH TECHNOLOGY LIM , SORE HANNAH FIONA , BOYLE ROBERT GEORGE , HAMLETT CHRISTOPHER , SAXTY GORDON , VERDONK MARINUS LEENDERT , WALKER DAVID WINTER , WOODHEAD STEVEN JOHN , HOWARD STEVEN
发明人： CANCER RESEARCH TECHNOLOGY LIM , SORE HANNAH FIONA , BOYLE ROBERT GEORGE , HAMLETT CHRISTOPHER , SAXTY GORDON , VERDONK MARINUS LEENDERT , WALKER DAVID WINTER , WOODHEAD STEVEN JOHN , HOWARD STEVEN
IPC分类号： C07D231/12 , A61K31/415 , A61P43/00 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
CPC分类号： C07D231/12 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
摘要： The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof; wherein A is a saturated hydrocarbon linker group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; L 1 is a bond or a linker selected from C 1 -C 4 alkenylene, C 1 -C 4 alkynylene, -CONR', -NR'CO, -S-, -C(O)-, -C(NR 11 )-, -C(S)-, -N(R 11 ) 2 , C(=CHR 11 ), -SO- and -SO 2- ; or L 1 together with t R 16 forms an 8-12 membered fused bicyclic heteroaryl ring system; L 3 is a bond or a linker selected from CONH and HNCO; provided that L 1 and L 3 cannot both be linkers simultaneously; and provided also that L 1 and L 3 cannot both be a bond simultaneously; R 16 is an optionally substituted 5- to 12-membered monocyclic or bicyclic carbocyclic or heterocyclic ring; L 2 is absent or is a linker selected from C]-C4 alkylene, Ci-C4 alkenylene, Ci-C4 alkynylene, -CONR'-, -NR'CO-, -O-, -S-, -C(O)-, C(=CHR 11 ), C(S)-, -N(R 11 ) 2 , C 3-4 cycloalkanediyl, -SO- and -SO2-; R 17 is absent or is C 1-6 alkyl or an optionally substituted 5 to 12 membered carbocyclic or heterocyclic ring; provided that when R 17 is absent, then L 2 is also absent; and R 2 , R 3 , R 4 , R 5 , R 11 and R' are as defined in the claims. Compounds (I) modulate (PKA) and (PKB).
摘要翻译：本发明提供式（I）化合物或其盐，溶剂合物，互变异构体或N-氧化物; 其中A是饱和烃连接基团; E是单环或双环碳环或杂环基; L 1是选自C 1 -C 4亚链烯基，C 1 -C 3链烯基的键或连接基团， -CONR'， - NR'CO，-S - ， - C（O） - ， - C（NR 11） - ， - C（S） - ，-N（R 11）2，C（= CHR 11），-SO-和-SO 2 - SUB>; 或L 1连同t R 16一起形成8-12元稠合双环杂芳基环系; L 3是选自CONH和HNCO的键或接头; 条件是L 1和L 3不能同时都是接头; 并且还提供了L 1和L 3不能同时是键; R 16是任选取代的5至12元单环或双环碳环或杂环; L 2不存在或是选自C 1 -C 4亚烷基，C 1 -C 4亚烯基，C 1 -C 4亚炔基，-CONR' - ， - NR'CO - ， - O - ， - S - ， - （O） - ，C（= CHR 11），C（S） - ， - N（R 11） C 3-4环烷二基，-SO-和-SO 2 - ; R 17不存在或为C 1-6烷基或任选取代的5至12元碳环或杂环; 条件是当R 17不存在时，L 2也不存在; 和R 2，R 3，R 4，R 5，R 11，和R'如权利要求中所定义。化合物（I）调节（PKA）和（PKB）。

7. 发明申请

WO2005002552A3 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS 审中-公开
标题翻译：苯并咪唑衍生物及其作为蛋白激酶抑制剂的用途
公开(公告)号：WO2005002552A3
公开(公告)日：2005-06-16
申请号：PCT/GB2004002824
申请日：2004-07-05
申请人： ASTEX TECHNOLOGY LTD , BERDINI VALERIO , O'BRIEN MICHAEL ALISTAIR , CARR MARIA GRAZIA , EARLY THERESA RACHEL , NAVARRO EVA FIGUEROA , GILL ADRIAN LIAM , HOWARD STEVEN , TREWARTHA GARY , WOOLFORD ALISON JO-ANNE , WOODHEAD ANDREW JAMES , WYATT PAUL
发明人： BERDINI VALERIO , O'BRIEN MICHAEL ALISTAIR , CARR MARIA GRAZIA , EARLY THERESA RACHEL , NAVARRO EVA FIGUEROA , GILL ADRIAN LIAM , HOWARD STEVEN , TREWARTHA GARY , WOOLFORD ALISON JO-ANNE , WOODHEAD ANDREW JAMES , WYATT PAUL
IPC分类号： A61K31/00 , A61K31/4184 , A61P31/10 , A61P35/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D403/04
CPC分类号： A61K31/5377 , A61K31/00 , A61K31/4184 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D513/04
摘要： The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I). Also included within formula (I) are the salts, solvates and N-oxides of the compounds.
摘要翻译：本发明提供具有作为细胞周期蛋白依赖性激酶抑制剂，糖原合成酶激酶-3和极光激酶的活性的化合物，其用于治疗由激酶介导的疾病状态和病症如癌症。化合物具有通式（I）。式（I）中还包括化合物的盐，溶剂合物和N-氧化物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式